StemCell Therapy

The success of the approved gene therapies has led to an upward surge in the interest of biopharmaceutical developers in this field, resulting in a significant boost in clinical research initiatives and several high value acquisitions

Roots Analysis has announced the addition of Gene Therapy Market (3rd Edition), 2019-2030 report to its list of offerings.

Encouraging clinical results across various metabolic, hematological and ophthalmic disorders have inspired research groups across the world to focus their efforts on the development of novel gene editing therapies. In fact, the gene therapy pipeline has evolved significantly over the past few years, with three products being approved in 2019 alone; namely Beperminogene perplasmid (AnGes), ZOLGENSMA (AveXis) and ZYNTEGLO (bluebird bio). Further, there are multiple pipeline candidates in mid to late-stage (phase II and above) trials that are anticipated to enter the market over the next 5-10 years.

To order this 550+ page report, which features 190+ figures and 355+ tables, please visit this link

Key Market Insights

Around 470 gene therapies are currently under developmentNearly 45% of pipeline drugs are in the clinical phase, while rest are in the preclinical / discovery stage. Gene augmented therapies presently represent 66% of the total number of such interventions that are in the pipeline. It is worth mentioning that majority of such product candidates are being developed as in vivo gene therapies.

More than 30% of clinical stage pipeline therapies are being designed for treating oncological disordersConsidering the overall pipeline, over 20% of product candidates are being developed to treat various types of cancers, followed by those intended for the treatment of metabolic (15%) and ophthalmic disorders (12%). It is also worth highlighting that adenovirus vectors are presently the preferred vehicles used for the delivery of anticancer gene therapies.

Over 60% of gene therapy developers are based in North AmericaOf the 110 companies developing gene therapies in the abovementioned region, 64 are start-ups, 26 are mid-sized players, while 18 are large and very large companies. Further, within this region, most of the developers are based in the US, which has emerged as a key R&D hub for advanced therapeutic products.

More than 31,000 patents have been filed / published related to gene therapies, since 2016Of these, 17% of patent applications / patents were related to gene editing therapies, while the remaining were associated with gene therapies. Leading assignees, in terms of the size of intellectual property portfolio, include (industry players) Genentech, GSK, Sangamo Therapeutics, Bayer and Novartis, (non-industry players) University of California, Massachusetts Institute of Technology, Harvard College, Stanford University and University of Pennsylvania.

USD 16.5 billion has been invested by both private and public investors, since 2014Around USD 3.3 billion was raised through venture capital financing, representing 20% of the total capital raised by industry players till June 2019. Further, there have been 28 IPOs, accounting for more than USD 2.2 billion in financing of gene therapy related initiatives. These companies have also raised significant capital in secondary offerings.

30+ mergers / acquisitions have been established between 2014 and 2019Examples of high value acquisitions reported in recent past include the acquisition of AveXis by Novartis (2018, USD 8,700 million) and Bioverativ by Sanofi (2018, USD 11,600 million).

North America and Europe are anticipated to capture over 85% of market share by 2030With a promising development pipeline and encouraging clinical results, the market is anticipated to witness an annualized growth rate of over 40% during the next decade. In addition to North America and Europe, the market in China / broader Asia Pacific region is also anticipated to grow at a relatively faster rate.

To request a sample copy / brochure of this report, please visit this link

Key Questions Answered

The USD 10 billion (by 2030) financial opportunity within the gene therapy market has been analyzed across the following segments:

The report features inputs from eminent industry stakeholders, according to whom gene therapies are likely to be the most promising treatment options for genetic disorders. The report includes detailed transcripts of discussions held with the following experts:

The research covers brief profiles, featuring an overview of the therapy, current development status and clinical results. Each profile includes information on therapeutic indication, targeted gene, route of administration, special designations, mechanism of action, dosage, patent portfolio, technology portfolio, clinical trials and recent developments (if available).

For additional details, please visit https://www.rootsanalysis.com/reports/view_document/gene-therapy-market-3rd-edition-2019-2030/268.html

or email [emailprotected]

Contact:Gaurav Chaudhary+1 (415) 800 3415+44 (122) 391 1091[emailprotected]

See more here:
Gene Therapy Market is projected to be worth USD 10 Billion by 2030, growing at an annualized rate of over 40%, claims Roots Analysis - PRnews Leader

Scientists working at the University of North Carolina, Chapel Hill reported in the Oct. 21, 2020, issue of Nature on the successful development of a one-time specific sequence-directed gene therapy approach using the combination of AAV with CRISPR technology that successfully prevented the presentation of Angelman syndrome throughout the lifetime of a mouse model.

Lifelong gene therapy has held promise for decades now as one of the only approaches that could possibly address many neurodevelopmental genetic disorders. But even after decades of research, gene therapy still possesses significant risks due to untoward random genomic insertions of vectors that could ultimately cause other genetic disorders.

Meanwhile, it has been known for decades now that adeno-associated virus (AAV) is a particularly powerful potential gene therapy vector because AAV integrates into the genome so well. However, the integration of AAV has always been random and so it inherently comes with significant risk.

This is the first time that a treatment for Angelman syndrome has been shown to correct this neurodevelopmental disorder.

Principal investigator, Mark Zylka, professor of Cell Biology and Physiology in the Neuroscience Center, University of North Carolina, Chapel Hill, told BioWorld Science, "The key really from what we can tell is going early in treatment. So for the animals that have the disorder we can identify them with genotyping. If you catch it early, you can treat them one time and it lasts forever as far as we can tell.

That longevity, he said, "contrasts with treatments that are in development using antisense technologies that usually have to be injected every 4 months or so, which is not ideal for a pediatric disorder that will last a lifetime."

Angelman syndrome is caused by loss of function of the maternal Ube3a allele, while the paternal allele is normally silenced by a very long antisense noncoding RNA known as Ube3a-ATS. Previously in a 2011 Nature publication Zylka and collaborators demonstrated that a class of drugs called topoisomerase inhibitors could reactivate the paternal allele by interfering with Ube3a-ATS. So Zylka knew that if the paternal copy of Ube3a can be turned on, this will provide the possibility of treating the condition.

Topoisomerase inhibitors, which include chemotherapy agents such as irinotecan and doxorubicin, are not a therapeutic option for Angelman syndrome due to their broad-spectrum nature and toxicity. But with the development of CRISPR combined with AAV, the researchers have now developed a tool to precisely hone in on specific regions of the genome.

First, the team screened 250 different RNA guided CRISPR/Cas9 constructs in cell culture until they identified the best one (Spjw33) reactivating the Ube3a-ATS allele. These clones had the good fortune to target Snord115 genes within the large Ube3a-ATS locus. The Snord genes are functionally redundant, with over 100 of them present in both mice and humans.

Ultimately the CRISPR/Cas9 with the cloned RNA guide was used to a specific region of the DNA, where DNA was inserted into the Snord115 gene of the Ube3a-ATS locus. The inserted DNA possessed a polyadenylation signal that caused the premature termination of the Ube3a-ATS noncoding RNA such that it no longer silenced the paternal expression of Ube3a.

With the Ube3a now made in the mouse, it fully developed and no longer presented with any phenotypes resembling Angelman syndrome throughout the life of the animal.

In short, instead of deleting the gene, this approach disrupted the Ube3a-ATS gene by stopping its full production prematurely. Only a small nonfunctioning part of the noncoding RNA was still produced in treated animals.

Earlier is better

The broad implications are that the study proves that Angelman syndrome can be treated and possibly prevented, if it is done early enough.

Previous studies showed that if turning on the paternal copy later, even within just a few days after birth in a mouse, this approach does not prevent Angelman syndrome.

Zylka said, "It is like with a building. You want to make sure the foundation is done correctly. Tons of time is put into the foundation. If there is a problem with the foundation, then when building on top of it, it is very hard and next to impossible to go back and fix the foundation. When the brain is developing, it is the initial foundation upon which the brain is built that is critical and you cannot really go back and fix it. So this study now shows that you can fix the problem if you catch it early enough by administering just a single treatment."

One encouraging result was the lack of gene therapy occurring in the mother. The team injected the vector into the fetus, but no gene therapy was detectable in the mother's liver and brain. Instead, the gene therapy was restricted to only the fetus. This was remarkable and very important since AAV is well known to particularly target the liver.

The technology to identify fetuses with the mutation that causes Angelman syndrome is already available and currently used in hospitals around the world. Techniques like amniocentesis, chorionic villus sampling, and even newer noninvasive technologies involving taking extra blood from the mom can now detect fetal DNA and cells to find out if there are any Angelman syndrome mutations.

However, there has not been a strong incentive to look for Angelman syndrome given that there are no therapeutic options at this point.

Zylka hopes to ultimately test the approach in the clinic. But first-time gene therapy technologies are often only given one shot in clinical trials and safety is of primary concern. So, extensive further research will be necessary to not throw away his shot (Wolter, J.M. et al. Nature 2020, Advanced publication).

Here is the original post:
Foundational research shows early gene therapy prevents Angelman syndrome - BioWorld Online

Early in the coronavirus pandemic, management at the North Hill Retirement Community a sprawling high-end campus for older adults in suburban Boston kept a wary eye on how the virus was sweeping through similar facilities with devastating, deadly consequences.

It took precautions to protect its residents, and when the order came down that by mid-July, all of its 400 staff members had to be tested for the virus every week, administrators scanned a list of approved tests provided by the Massachusetts health department and selected a vendor a Boston-based DNA lab named Orig3n that had developed its own test for the novel coronavirus.

North Hill was soon to learn, not all Covid-19 tests are created equal. In a vast, confusing landscape populated by hundreds of different private companies and labs, some tests are proving problematic, especially when used to screen people who have no symptoms of Covid-19. A STAT investigation found that top officials at the U.S. Department of Health and Human Services ended already-minimal oversight of these so-called laboratory developed tests in mid-August, despite being informed that the tests were plagued with quality issues.

advertisement

It was just two weeks earlier that North Hills administrators, after going months with only one positive test for Covid-19, had been informed that 19 staff members tested positive for the virus at the same time.

It was really out of the blue, said Ted Owen, North Hill president and CEO. The numbers looked strange to us, that suddenly there would be this big thing.

advertisement

State public health investigators were called in to verify the test results, and meanwhile, Owens said, There was a week of absolute pandemonium. Staffers were sent home to nervous families, waiting for symptoms to emerge, while residents and their families waited to see if the virus had spread among the vulnerable, older population of North Hill. In the end, the problem was not a viral outbreak but a testing issue. All 19 of the results were false positives; none of the staffers actually had Covid-19.

North Hills false positives were not isolated. A state investigation in August found 383 false coronavirus positives in that period from Orig3n tests, which had been used by about 60 nursing homes in the state. The state health department suspended Orig3ns testing, demanding the company address contamination and documentation issues. Orig3n told STAT it faults human error for its testing problems.

The Orig3n test is just one of dozens that hospitals, university researchers, and private labs rushed to make as the pandemic spread across the U.S. All these laboratory developed tests, known as LDTs, use the same basic PCR technology to identify genetic material from the coronavirus in patient swabs, but their performance can vary widely. They are being used across the country by states, private employers, sports leagues, and schools to try to manage the pandemic, yet they are something of a black box. Because they fall into a regulatory gray area, nobody outside the labs themselves knows how accurate they are not even the health care providers who use them.

Nor is it clear how many LDTs for Covid-19 are on the market. The Food and Drug Administration doesnt know for sure, but acknowledges the number is not small; the agency has granted emergency authorization to more than 200 diagnostic tests, and LDTs may account for more than half of tests in use, an FDA official estimated. These lab PCR tests are essentially the same as ones sold by manufacturers like Abbott and Roche, but theyre regulated differently and are exempt from oversight by the FDA.

In February, as the coronavirus was starting to spread across the U.S., the FDA began requiring these labs to apply for an emergency use authorization, as it had in previous public health emergencies like the H1N1 flu pandemic in 2009. The bar was set low to get tests on the market fast, labs were allowed to start using them without waiting for FDA sign-off and the standards for approval were far less than would normally be required. Labs merely had to show reasonable accuracy detecting the virus on contrived test samples that werent obtained from actual patients.

Then this summer, the Department of Health and Human Services directed the FDA to stop requiring emergency authorization for this segment of the testing market. The Centers for Medicare and Medicaid Services retained oversight of the labs, but it ensures only that labs meet quality standards, not that specific tests work. The decision meant the FDA has no way to track problems with Covid-19 LDTs including false-positive or false-negative results or even which labs are marketing these tests.

An HHS spokesperson said the decision was made for purely legal reasons, based on its Office of General Counsels determination that the FDA does not have jurisdiction over lab-developed tests.

This deregulatory action ensures compliance with law, is responsive to multiple Trump Administration Executive Orders and better prepares us for future pandemics while maintaining regulatory safeguards for quality and accuracy, HHS chief of staff Brian Harrison said in a statement.

But STAT has learned that before the decision, HHS and its general counsel, Robert Charrow, were alerted to major concerns about many of the LDTs for detecting the coronavirus, which had been identified during the FDAs review process.

Another FDA official, speaking on background, told STAT that data on problems with LDT accuracy and performance were sent by the FDA to HHS at the beginning of August, and were seen by Charrow before the decision to revoke FDA authority over LDTs, announced on Aug. 20. This officialwas on multiple phone calls with FDA colleagues and scientists in which the submission of data to HHS was discussed, including with people who had gathered and compiled the data and who were expressing extreme frustration with HHS for, as they described it, suppressing the data.

The data became public in a September article in the New England Journal of Medicine, in which two FDA officials outlined how the emergency use authorization process enables the agency to track the safety and problems with tests, but HHS earlier knowledge of the data has not been previously reported.

In the first months of the pandemic and testing rollouts, the FDA analyzed 125 EUA requests from laboratories, and found design or validation problems with 82, while several have been denied authorization, wrote FDAs Jeffrey Shuren, director of the Center for Devices and Radiological Health, and Timothy Stenzel, director of the FDA Office of In Vitro Diagnostics and Radiological Health. In most cases, the EUA process allowed the agency to work with labs to correct problems, they noted.

No test is 100 percent accurate and performance can vary within populations, they wrote. Covid-19 diagnostic tests may be less accurate in asymptomatic or low-risk populations and in persons who shed little virus or are early or late in the course of illness.

In a later interview, Shuren said the FDAs oversight role is critical in monitoring tests for safety and accuracy and keeping problematic tests off the market.

The value of FDA oversight of tests is that we are able to review and rely on the science to better understand whether or not a product works and how well it works, he said. If were not reviewing something, we cant do that.

Responding to criticism of the HHS decision, Charrow, the general counsel, said in a statement,It is false to say that this will lead to unregulated, low-quality COVID-19 tests. Every single COVID-19 test in the United States will still be regulated at the federal level. This simply removes an additional regulatory barrier that at most other times is not required.

Alberto Gutierrez, former director of the FDA Office of In Vitro Diagnostics and Radiological Health, who was with the agency for 25 years, said the current chaos in testing could have been prevented if the FDA and HHS were working together to track problems and safety and get the best tests to market.

The problem with LDTs is there are a lot of different laboratories and there are no real standards because the tests are developed by the laboratories, he said. Theres no bar to meet. You have very good laboratories that are very thorough, and you have some that cut corners.

In early October, three Democratic members of the U.S. House Reps. Frank Pallone Jr. of New Jersey, the chairman of the Energy and Commerce Committee, Anna Eshoo of California, and Diana DeGette of Colorado wrote to HHS Secretary Alex Azar, demanding answers about the agencys decision to end FDA oversight and tracking of lab-developed tests. During the Covid-19 pandemic, they said, FDA jurisdiction over LDTs is warranted because as former FDA Commissioner Scott Gottlieb recently wrote, in public health emergencies, diagnostic tests not only diagnose diseases that arent completely understood, but help guide analyses of disease progression and risks to public health.

The testing company at the center of this summers debacle in Massachusetts where it was also deployed to test people who are homeless says it is working to improve its Covid-19 test, which remains off the market there and in other states where it was used, including North Carolina. Weve taken extraordinary steps to work through this challenging time and hope to be able to bring our capacity carefully back online to help address this pandemic, said Orig3n CEO Robin Smith.

Orig3n was granted emergency authorization in April, before HHS dropped the requirement. Under an EUA, test makers are supposed to report to the FDA when things go wrong including false results. But few do. A review of the agencys public database for testing issues shows only 657 reports related to Covid-19 diagnostic tests as of Sept. 30, out of more than 100 million tests performed by that point. This means the vast majority of false Covid-19 results including all of the Orig3n testing errors are simply never reported.

The FDA acknowledges underreporting is rampant, limiting the databases usefulness for spotting problematic tests. Especially for LDTs, it relies on essentially an honor system, expecting labs to report on themselves. Without better tracking and oversight from the federal government, some agency officials told STAT, they fear testing problems will continue as the pandemic worsens through the fall and winter, with patients and medical providers flying blind on which tests can be trusted.

More:
HHS eased oversight of Covid-19 tests though it knew of problems - STAT

Global Cell Banking Outsourcing Market: Overview

The global cell banking outsourcing market is likely to be driven by the rising demand for biopharmaceutical production targeting novel active sites, stem cell therapy, and gene therapy. A cell bank is a facility storing cells extracted from various organ tissue and body fluids so as to cater to the needs of the future. The cell banks make storage of cells with an elaborate characterization of the entire cell line as it reduces the possibilities of cross contamination. These benefits are estimated to fuel expansion of the global cell banking outsourcing market over the timeframe of assessment, from 2020 to 2030.

Read Report Overview - https://www.transparencymarketresearch.com/cell-banking-outsourcing-market.html

Cell banking outsourcing industries engage testing, characterization, storage, and collection of tissues, cell lines, and the cells. These activities are done to assist in the production of biopharmaceuticals and in the research and development activities so as to ensure minimum adverse effects and high effectiveness. The procedure of the cell storage involves first proliferation of cells, which then multiplies in a huge number of identical cells and is then put inside cryovials safety for use in future. Cells are primarily utilized in the production of regenerative medicine. A surge in the number of cell banks together with the high demand for stem cell therapies is likely to work in favor of the global cell banking outsourcing market over the tenure of analysis, from 2020 to2030.

The global cell banking outsourcing market has been segmented on the basis of four important parameters, which are bank type, phase, cell type, and region.

Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=79685

Global Cell Banking Outsourcing Market: Notable Developments

The global cell banking outsourcing market is considered a fairly competitive market and is marked with the presence of many leading market players. The companies in this market are forging mergers, partnerships, and collaborations so as to gain larger revenue and market share. The following development is expected to play an important role in the market:

Request for Analysis of COVID-19 Impact on Cell Banking Outsourcing Market- https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=1645

Global Cell Banking Outsourcing Market: Key Trends

The global cell banking outsourcing market is characterized by the presence of the following restraints, drivers, and opportunities.

High Demand for Stem Cell Therapies to Trigger Growth of the Market

The rising number of stem cell therapies across the globe primarily influences the global cell banking outsourcing market. According to a survey conducted by World Network for Blood and Marrow Transplantation (WBMN), nearly 1 million hematopoietic stem cell transplantation processes were conducted in between 2006 to 2014. These figure comprised removal of stem cells procedures from peripheral blood or bone marrow, proliferating, and then finally storing them cell banks for future use by patients. Stem cell therapies are able to multiple disease, such as amyotrophic lateral sclerosis, type 1 diabetes, cancer, Alzheimer's disease, Parkinson's disease, and so on. Ability to cure such a wide variety of diseases is expected to propel growth of the global cell banking outsourcing market in the years to come.

Request for Custom Research - https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=1645

Global Cell Banking Outsourcing Market: Geographical Analysis

North America is expected to dominate the global cell banking outsourcing market throughout the timeframe of analysis, from 2020 to 2030. Such high growth of the North America market is ascribed to the increased production of antibiotics, therapeutics protein, and vaccines. In addition, presence of several biopharmaceutical companies in the region is anticipated to foster growth of the cell banking outsourcing market in North America in the near future.

Pre Book Cell Banking Outsourcing Market Report - https://www.transparencymarketresearch.com/checkout.php?rep_id=1645&ltype=S

Browse More Trending Reports by Transparency Market Research:

Healthcare Fraud Detection Market: https://www.transparencymarketresearch.com/healthcare-fraud-detection-market.html

Epinephrine Injection Market: https://www.transparencymarketresearch.com/epinephrine-injection-market.html

Dermal Regeneration Matrix Device Market: https://www.transparencymarketresearch.com/dermal-regeneration-matrix-device-market.html

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.

ContactMr. Rohit BhiseyTransparency Market ResearchState Tower,90 State Street,Suite 700,Albany NY - 12207United StatesUSA - Canada Toll Free: 866-552-3453Email: sales@transparencymarketresearch.comWebsite: https://www.transparencymarketresearch.com/

Read the original:
Cell Banking Outsourcing Market: High Demand for Stem Cell Therapies to Trigger Growth of the Market - BioSpace

AllTheResearchs published a research report on the Canine Stem Cell Therapy market, which represents a study for the period from 2020 to 2026. The research provides a near look at the market scenario and dynamics impacting its growth. This report highlights the crucial developments along with other events happening in the market which are marking on the growth and opening doors for future growth in the coming years. Additionally, the report is built based on the macro- and micro-economic factors and historical data that can influence the growth.

The global Canine Stem Cell Therapy market was valued at US$ 118.5 Mn in 2018 and is expected to reach US$ 240.7 Mn in 2026, growing at a CAGR of 9.3% during the forecast period.

Request for Sample with Complete TOC and Figures & Graphs @ https://www.alltheresearch.com/sample-request/206

Key Players:

The global Canine Stem Cell Therapy market has been comprehensively analyzed and the different companies that occupy a large percentage of the market share in the regions mentioned have been listed out in the report. Industry trends that are popular and are causing a resurgence in the market growth are identified. A strategic profile of the companies is also carried out to identify the various subsidiaries that they own in the different regions and who are responsible for daily operations in these regions.

The Key Players Covered in Canine Stem Cell Therapy Market Study are:

How Report will help you to make decisions for business:

Before purchasing the report, lets discuss with the analyst @ https://www.alltheresearch.com/speak-to-analyst/206

Canine Stem Cell Therapy Market Segmentation

Canine Stem Cell Therapy market is split by Type and by Application. For the period 2015-2026, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

Market Segmentation by Type:

Market Segmentation by Applications:

COVID-19 Impact on Canine Stem Cell Therapy Market:

The outbreak of COVID-19 has brought along a global recession, which has impacted several industries. Along with this impact COVID Pandemic has also generated few new business opportunities for Canine Stem Cell Therapy Market. Overall competitive landscape and market dynamics of Canine Stem Cell Therapy has been disrupted due to this pandemic. All these disruptions and impacts has been analysed quantifiably in this report, which is backed by market trends, events and revenue shift analysis. COVID impact analysis also covers strategic adjustments for Tier 1, 2 and 3 players of Canine Stem Cell Therapy Market.

Get Brief Information on Pre COVID-19 Analysis and Post COVID-19 Opportunities in Canine Stem Cell Therapy Market @ https://www.alltheresearch.com/impactC19-request/206

Research objectives:

Browse Full Research report along with TOC, Tables & Figures: https://www.alltheresearch.com/report/206/Canine Stem Cell Therapy

About AllTheResearch:

AllTheResearch was formed with the aim of making market research a significant tool for managing breakthroughs in the industry. As a leading market research provider, the firm empowers its global clients with business-critical research solutions. The outcome of our study of numerous companies that rely on market research and consulting data for their decision-making made us realise, that its not just sheer data-points, but the right analysis that creates a difference.While some clients were unhappy with the inconsistencies and inaccuracies of data, others expressed concerns over the experience in dealing with the research-firm. Also, same-data-for-all-business roles was making research redundant. We identified these gaps and built AllTheResearch to raise the standards of research support.

FOR ALL YOUR RESEARCH NEEDS, REACH OUT TO US AT:

Contact Name: Rohan S.

Email: [emailprotected]

Phone: +1 (407) 768-2028

Read more:
Canine Stem Cell Therapy Market: Market Growth Factors, Applications, Regional Analysis, Key Players and Forecasts by 2026 - PRnews Leader

The global stem cell and regenerative medicines market should grow from $21.8 billion in 2019 to reach $55.0 billion by 2024 at a compound annual growth rate (CAGR) of 20.4% for the period of 2019-2024.

Report Scope:

The scope of this report is broad and covers various type of product available in the stem cell and regenerative medicines market and potential application sectors across various industries. The current report offers a detailed analysis of the stem cell and regenerative medicines market.

The report highlights the current and future market potential of stem cell and regenerative medicines and provides a detailed analysis of the competitive environment, recent development, merger and acquisition, drivers, restraints, and technology background in the market. The report also covers market projections through 2024.

Click Here to Get Sample Premium Report @ https://www.trendsmarketresearch.com/report/sample/11723

The report details market shares of stem cell and regenerative medicines based on products, application, and geography. Based on product the market is segmented into therapeutic products, cell banking, tools and reagents. The therapeutics products segments include cell therapy, tissue engineering and gene therapy. By application, the market is segmented into oncology, cardiovascular disorders, dermatology, orthopedic applications, central nervous system disorders, diabetes, others

The market is segmented by geography into the following regions: North America, Europe, Asia-Pacific, South America, and the Middle East and Africa. The report presents detailed analyses of major countries such as the U.S., Canada, Mexico, Germany, the U.K. France, Japan, China and India. For market estimates, data is provided for 2018 as the base year, with forecasts for 2019 through 2024. Estimated values are based on product manufacturers total revenues. Projected and forecasted revenue values are in constant U.S. dollars, unadjusted for inflation.

Report Includes:

28 data tables An overview of global markets for stem cell and regenerative medicines Analyses of global market trends, with data from 2018, estimates for 2019, and projections of compound annual growth rates (CAGRs) through 2024 Details of historic background and description of embryonic and adult stem cells Information on stem cell banking and stem cell research A look at the growing research & development activities in regenerative medicine Coverage of ethical issues in stem cell research & regulatory constraints on biopharmaceuticals Comprehensive company profiles of key players in the market, including Aldagen Inc., Caladrius Biosciences Inc., Daiichi Sankyo Co. Ltd., Gamida Cell Ltd. and Novartis AG

Summary

The global market for stem cell and regenerative medicines was valued at REDACTED billion in 2018. The market is expected to grow at a compound annual growth rate (CAGR) of REDACTED to reach approximately REDACTED billion by 2024. Growth of the global market is attributed to the factors such as growingprevalence of cancer, technological advancement in product, growing adoption of novel therapeuticssuch as cell therapy, gene therapy in treatment of chronic diseases and increasing investment fromprivate players in cell-based therapies.

In the global market, North America held the highest market share in 2018. The Asia-Pacific region is anticipated to grow at the highest CAGR during the forecast period. The growing government funding for regenerative medicines in research institutes along with the growing number of clinical trials based on cell-based therapy and investment in R&D activities is expected to supplement the growth of the stem cell and regenerative market in Asia-Pacific region during the forecast period.

Reasons for Doing This Study

Global stem cell and regenerative medicines market comprises of various products for novel therapeutics that are adopted across various applications. New advancement and product launches have influenced the stem cell and regenerative medicines market and it is expected to grow in the near future. The biopharmaceutical companies are investing significantly in cell-based therapeutics. The government organizations are funding research and development activities related to stem cell research. These factors are impacting the stem cell and regenerative medicines market positively and augmenting the demand of stem cell and regenerative therapy among different application segments. The market is impacted through adoption of stem cell therapy. The key players in the market are investing in development of innovative products. The stem cell therapy market is likely to grow during the forecast period owing to growing investment from private companies, increasing in regulatory approval of stem cell-based therapeutics for treatment of chronic diseases and growth in commercial applications of regenerative medicine.

Products based on stem cells do not yet form an established market, but unlike some other potential applications of bioscience, stem cell technology has already produced many significant products in important therapeutic areas. The potential scope of the stem cell market is now becoming clear, and it is appropriate to review the technology, see its current practical applications, evaluate the participating companies and look to its future.

The report provides the reader with a background on stem cell and regenerative therapy, analyzes the current factors influencing the market, provides decision-makers the tools that inform decisions about expansion and penetration in this market.

More Info of Impact Covid19 @ https://www.trendsmarketresearch.com/report/covid-19-analysis/11723

More:
Stem Cell and Regenerative Therapy Market to Remain Balanced During the the COVID-19 Period - re:Jerusalem

Global Stem Cell Therapy Market Overview:

The report includes background information along with a detailed overview of the global Stem Cell Therapy market. This data explains the development of the Stem Cell Therapy market as well as technological advances. The report also covers various end-user applications in the Stem Cell Therapy market. The market has been divided into several segments based on specific data that represents the total market share by the forecast year 2025. In addition, the Stem Cell Therapy market data is derived from competitive partners, key players and their revenues over the years. It also includes data on numerous players from all over the world, leading to huge fragmentation of the global Stem Cell Therapy market. The forecast for 2020-2025 highlights the growth of the Stem Cell Therapy market in terms of CAGR.

The impact of the Covid-19 outbreak on the Stem Cell Therapy industry, including potential opportunities and challenges, driving forces and risks, is also explored and evaluated in this study. Based on various scenarios (optimistic, pessimistic, very optimistic, most likely, etc.), we present an estimate of the impact of Covid-19 on a Stem Cell Therapy writer and a forecast for market growth for 2020-2025.

Get A Sample Copy of Research Report at: https://www.adroitmarketresearch.com/contacts/request-sample/691?utm_source=bh

Global Stem Cell Therapy Market Research analyzes vital geographic regions, provides a detailed assessment, including key market trends in accordance with their growth, future technologies, industry drivers, problems, regulatory policies, profiles of key players.

The research process included the study of various factors affecting the Stem Cell Therapy industry, including government policy, market environment, competitive environment, historical data, key technological advances and current trends shaping the market, current market trends and technological progress in related industries, and market risks, opportunities, market barriers and challenges.

Read Complete Report with TOC @ https://www.adroitmarketresearch.com/industry-reports/stem-cell-therapy-market?utm_source=bh

Competitive Analysis:

Major players place great emphasis on technological innovation to improve efficiency levels. The industrys growth prospects are reflected in ensuring continual improvement in player processes and optimal strategies used by companies to combat the COVID-19 situation. The company profile section of players such as Marriott International, Hilton Worldwide and AccorHotels includes relevant information such as name, subsidiaries, website, headquarters, market position, market growth / bust, historical background or comments on growth, as well as the top 3 closest competitors by market capitalization. / income along with contact information. Each companys revenues, annual growth, gross and operating margins are presented in an easy-to-understand tabular format over the past 5 years and in a separate section on recent events such as mergers and acquisitions, patent approvals, new project launches, etc.

Stem Cell Therapy Market Segmentation

By Types:

Based on cell source, the market has been segmented into,

Adipose Tissue-Derived Mesenchymal SCsBone Marrow-Derived Mesenchymal SCsEmbryonic SCsOther Sources

By Applications:

Based on therapeutic application, the market has been segmented into,

Musculoskeletal DisordersWounds & InjuriesCardiovascular DiseasesGastrointestinal DiseasesImmune System DiseasesOther Applications

Research Methodology

The Global Stem Cell Therapy Market Research was conducted by a team of industry experts and professionals with deep market knowledge. Researchers determine the intensity of competition and also study the opportunities for growth in the market using the parameters of the Porters five forces model method. The report also conducts a SWOT analysis of the Stem Cell Therapy market, identifying strengths, weaknesses, opportunities and threats in the market. The report will help companies entering the market get a complete picture of current and future market trends.

Market Dynamics

This report explores various market factors driving the rapid growth and expansion of the Stem Cell Therapy market. The report includes a detailed study of the history of pricing, supply and demand dynamics, price trends, etc., which play a huge role in the market. The report also examines the impact of government initiatives and policies on market stability. The report also analyzes market opportunities and weaknesses, which can help companies develop appropriate strategies.

Some of the major objectives of this report:

1. To provide a detailed analysis of the market structure along with the forecast of the various segments and sub-segments of the global Stem Cell Therapy Market.2. To provide insights about factors affecting market growth. To analyze the Stem Cell Therapy Market based on various factors- price analysis, supply chain analysis, porter five force analyses, etc.3. To provide historical and forecast revenue of the Stem Cell Therapy Market segments and sub-segments with respect to four main geographies and their countries- North America, Europe, Asia, and the Rest of the World.4. Country-level analysis of the market with respect to the current market size and future prospective.5. To provide country-level analysis of the market for segment by application, product type, and sub-segments.6. To provide strategic profiling of key players in the market, comprehensively analyzing their core competencies, and drawing a competitive landscape for the market.7. Track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the Stem Cell Therapy Market.

Table of Contents: Stem Cell Therapy Market

Chapter 1. Stem Cell Therapy Market OverviewChapter 2: State of the World Market and Forecasts by RegionChapter 3: State of the World Market and Forecast by TypeChapter 4: Global Market State and Prospects for the Downstream SectorsChapter 5: Analyzing Market DriversChapter 6: The State of Market Competition of Major ProducersChapter 7: Major Producers and Market DataChapter 8: Exploration and Production Market AnalysisChapter 9: Cost and Gross Profit AnalysisChapter 10: Analyzing Marketing StatusChapter 11: Conclusion of the Market ReportChapter 12: Research Methodology and Background Information

Make an Inquiry of the Stem Cell Therapy Market Report at: https://www.adroitmarketresearch.com/contacts/enquiry-before-buying/691?utm_source=bh

About Us :

Contact Us :

Ryan JohnsonAccount Manager Global3131 McKinney Ave Ste 600, Dallas,TX75204, U.S.A.Phone No.: USA: +1 972-362 -8199/ +91 9665341414

Original post:
Stem Cell Therapy Market Size 2020 Growth Analysis and Share by Key Players, Trends with Revenue with COVID-19 Impact Forecast to 2026 - PRnews...

Complete study of the global Stem Cell Therapy market is carried out by the analysts in this report, taking into consideration key factors like drivers, challenges, recent trends, opportunities, advancements, and competitive landscape. This report offers a clear understanding of the present as well as future scenario of the global Stem Cell Therapy industry. Research techniques like PESTLE and Porters Five Forces analysis have been deployed by the researchers. They have also provided accurate data on Stem Cell Therapy production, capacity, price, cost, margin, and revenue to help the players gain a clear understanding into the overall existing and future market situation.

The global Stem Cell Therapy market report reveals pertinent data on segment performance, growth potential in the coming years as well as vendor and manufacturer activities, aligning appropriately with consumption and production developments.

Get Exclusive Sample of Report on Stem Cell Therapy market is available @ https://www.adroitmarketresearch.com/contacts/request-sample/691

The pandemic of Coronavirus (COVID-19) has affected every aspect of life worldwide. This has brought along several changes in market conditions. The rapidly changing industry scenario and initial and future assessment of the impact are covered in the report. The Stem Cell Therapy market report puts together a concise analysis of the growth factors influencing the current business scenario across various regions. Significant information pertaining to the industry analysis size, share, application, and statistics are summed in the report in order to present an ensemble prediction.

Some of the key reader queries that have been adequately addressed in the report include, top vendors and their growth triggering business strategies, regional outlook and growth hotspot identification, followed by prominent growth retardants, challenges and threat probability which result in dwarfed growth outlook. Further, to instill new market participation amongst novel enthusiast, this report clearly focuses teeming business opportunities that ensure smooth rise despite odds and growing competition.

Browse the complete report Along with TOC @ https://www.adroitmarketresearch.com/industry-reports/stem-cell-therapy-market

Competitive Landscape

It is important for every market participant to be familiar with the competitive scenario in the global Stem Cell Therapy industry. In order to fulfill the requirements, the industry analysts have evaluated the strategic activities of the competitors to help the key players strengthen their foothold in the market and increase their competitiveness.

Stem Cell Therapy Market Segmentation

Type Analysis of Stem Cell Therapy Market:

Based on cell source, the market has been segmented into,

Adipose Tissue-Derived Mesenchymal SCsBone Marrow-Derived Mesenchymal SCsEmbryonic SCsOther Sources

Applications Analysis of Stem Cell Therapy Market:

Based on therapeutic application, the market has been segmented into,

Musculoskeletal DisordersWounds & InjuriesCardiovascular DiseasesGastrointestinal DiseasesImmune System DiseasesOther Applications

Key questions answered in the report:

1.What is the growth potential of the Stem Cell Therapy market?2.Which product segment will grab a lions share?3.Which regional market will emerge as a frontrunner in coming years?4.Which application segment will grow at a robust rate?5.What are the growth opportunities that may emerge in Stem Cell Therapy industry in the years to come?6.What are the key challenges that the global Stem Cell Therapy market may face in future?7.Which are the leading companies in the global Stem Cell Therapy market?8.Which are the key trends positively impacting the market growth?9.Which are the growth strategies considered by the players to sustain hold in the global Stem Cell Therapy market?

If you have any questions on this report, please reach out to us @ https://www.adroitmarketresearch.com/contacts/enquiry-before-buying/691

About Us :

Contact Us :

Ryan JohnsonAccount Manager Global3131 McKinney Ave Ste 600, Dallas,TX75204, U.S.A.Phone No.: USA: +1 972-362 -8199/ +91 9665341414

Read more:
Stem Cell Therapy Market | Growth Strategies Adopted By Top Key Players,Future Trends ,Application Worldwide And Assessment To 2026 - PRnews Leader

Fremont, CA , Oct. 28, 2020 (GLOBE NEWSWIRE) -- APstem Therapeutics, Inc., a private biopharmaceutical company developing breakthrough stem cell therapies, today announced the completion of an INitial Targeted Engagement for Regulatory Advice on CBER ProducTs (INTERACT) meeting with the U.S. Food and Drug Administration (FDA) Center for Biologics Evaluation and Research (CBER) Office of Tissues and Advanced Therapies (OTAT). The meeting, which included CBER OTAT staff together with the APstem team, focused on the development plan for AP-Skin-01, a novel off-the-shelf allogeneic stem cell product derived from adult pluripotent stem cells (APSCs) for the initial treatment of diabetic ulcers.

Previous efforts to treat diabetic ulcers have been hampered by persistent inflammation, ischemia and delayed re-epithelialization, which together have posed an insurmountable challenge for drug developers. APstems proprietary stem cell technologies and unique attributes of APSCs may circumvent these obstacles. Preclinical results generated to date by APstem support the potential of AP-Skin-01 to treat difficult-to-heal diabetic ulcers by accelerating healing. AP-Skin-01 is designed to provide full skin structural reconstruction with less scar formation, promote angiogenesis and reduce inflammation during the repair process.

The INTERACT meeting we conducted with the FDA is an important first step in our development of AP-Skin-01. We considered the meeting to be very successful, with productive feedback from the FDA reviewers and strong alignment of APstems development approach for AP-Skin-01, said Dr. Min Hu, CEO and president of APstem Therapeutics. I would like to thank the reviewers from FDA CBER OTAT for their time and helpful guidance. We look forward to continuing our planned pre-clinical work into 2021.

Dr. Jane Lebkowski, APstems scientific advisor and an expert in the development of cell and gene therapies, added: The field of chronic diabetic wounds remains a critical unmet medical need in the expanding diabetic population worldwide. This new therapy has high potential to accelerate full skin regeneration. Therefore, we are grateful for FDAs positive feedback to accelerate the development of this product that could treat millions of patients.

INTERACT is the first available FDA interaction and is a key step in the pathway towards an Investigational New Drug (IND) application, the first regulatory step before experimental therapies may be tested in human clinical studies.

About APstem Therapeutics, Inc.

APstem Therapeutics is a biopharmaceutical company dedicated to discovering, developing, manufacturing, and commercializing novel stem cell therapies. APstems breakthrough stem cell therapy platform using our unique APSCs can be applied to multiple indications, including skin (diabetic ulcers), liver, lungs, bone/cartilage, heart, neuron and other tissues. For more information, please visit http://www.apstemtx.com.

Read the rest here:
APstem Therapeutics Announces Successful FDA INTERACT Meeting Regarding AP-Skin-01, an Off-the-Shelf Allogeneic Stem Cell Product for the Treatment of...

The report on Global Stem Cell Therapy Market is a dependable point of reference heralding high accuracy business decisions on the basis of thorough research and observation by seasoned research professionals at CMI Research. The report on global Stem Cell Therapy market evidently highlights the causal factors such as demand analysis, trend examination, and technological milestones besides manufacturing activities that have been systematically touched upon to instigate systematic growth projection.

This CMI Research report on global Stem Cell Therapy market systematically studies and follows noteworthy progresses across growth trends, novel opportunities as well as drivers and restraints that impact growth prognosis.

Free Sample Report + All Related Graphs & Charts @:https://www.coherentmarketinsights.com/insight/request-sample/2848

Which market players and aspiring new entrants may witness seamless entry?

Magellan, Medipost Co., Ltd, Osiris Therapeutics, Inc., Kolon TissueGene, Inc., JCR Pharmaceuticals Co., Ltd., Anterogen Co. Ltd., Pharmicell Co., Inc., and Stemedica Cell Technologies, Inc.

Predicting Scope: Global Stem Cell Therapy Market, 2020-2027

Elaborate research proposes global Stem Cell Therapy market is likely to experience an impressive growth through the forecast span, 2020-2027, ticking a robust CAGR of xx% USD. The Stem Cell Therapy market is anticipated to demonstrate a whopping growth with impressive CAGR valuation. The Stem Cell Therapy market is also likely to maintain the growth spurt showing signs of steady recovery.

For appropriate analysis of all the market relevant information as well emerging trends and historical developments in the Stem Cell Therapy market, CMI Research has referred to various primary and secondary research practices and contributing factors.

Regional Overview: Global Stem Cell Therapy Market

The report specifically sheds light upon note-worthy business discretion, popular trends investment probabilities aligning with budding opportunities as well as breakthrough developments in policies and monetary inclination echoing investor preferences in Stem Cell Therapy space.

Competitive Landscape: Global Stem Cell Therapy Market

Further in the report, readers are presented with minute details pertaining to significant company profiles, product development, on pricing, production and vital information on raw material and equipment developments also form crucial report contents in this CMI Research report.

Have Any Query? Ask Our Expert @: https://www.coherentmarketinsights.com/insight/request-customization/2848

Segmentation Based on Stem Cell Therapy Market Types:

By Cell Source:Adult Stem CellsInduced Pluripotent Stem CellsEmbryonic Stem CellsOthersGlobal Stem Cell Therapy Market, By Application:Musculoskeletal DisordersWounds and InjuriesCancerAutoimmune disordersOthers

Global Stem Cell Therapy Market Size & Share, By Regions and Countries/Sub-regions:

Asia Pacific: China, Japan, India, and Rest of Asia Pacific

Europe: Germany, the UK, France, and Rest of Europe

North America: the US, Mexico, and Canada

Latin America: Brazil and Rest of Latin America

Middle East & Africa: GCC Countries and Rest of Middle East & Africa

The regional analysis segment is a highly comprehensive part of the report on the global Stem Cell Therapy market. This section offers information on the sales growth in these regions on a country-level Stem Cell Therapy market.

The historical and forecast information provided in the report span between2020 and 2027. The report provides detailed volume analysis and region-wise market size analysis of the market.

Report Investment, a Priority: Explains CMI Research

This report also helps market participants to organize R&D activities aligning with exact market requirements

The report resonates critical findings on decisive factors such as downstream needs and requirement specifications as well as upstream product and service development

The report aids in reader comprehension of the market based on dual parameters of value and volume.

This CMI Research initiated research output on Stem Cell Therapy market is a ready-to-refer handbook of noteworthy cues for easy adoption by market players and stakeholders

CMI Research skillfully underpins a vivid segment analysis of the global Stem Cell Therapy market, rendering appropriate inputs about the revenue generation capabilities of each segment.

Buy this research report @: https://www.coherentmarketinsights.com/insight/buy-now/2848

Thanks for reading our report. If you have any further questions, please contact us. Our team will provide you with the report tailored to your needs.

About Us:

Coherent Market Insightsis a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contacts Us: +1-206-701-6702Email:[emailprotected]Web:https://www.coherentmarketinsights.com/

Read the original here:
Stem Cell Therapy Market Industry Research Report, Growth Trends and Competitive Analysis 2020-2027: Magellan, Medipost Co., Ltd, Osiris Therapeutics,...

NK Cell Therapy and Stem Cell Therapy Market provides an in-depth insight into Sales and Trends Forecast: 2020-2025:

Global NK Cell Therapy and Stem Cell Therapy 2020 Report consists of important factors such as the latest trends, performance drivers, key players, revenue, growth rate and volume sales, and consumer insights. The most recent report by regal intelligence on global NK Cell Therapy and Stem Cell Therapy market analyses the impact of COVID 19 on the industry. The reports comprehend the global industry outlook in the light of the current market situation, trends, prominent players in the industry, and how these factors are expected to boost the NK Cell Therapy and Stem Cell Therapy market during the forecast period. The research study by regal intelligence analyses factors that are dynamic and will affect the NK Cell Therapy and Stem Cell Therapy market in the near future.

Global NK Cell Therapy and Stem Cell Therapy market competition by TOP MANUFACTURERS, with production, price, revenue (value) and each manufacturer including

Chipscreen Biosciences, Innate Pharma SA, Osiris Therapeutics, Chiesi Pharmaceuticals, Molmed, JCR Pharmaceutical, Altor BioScience Corporation, Affimed NV, Takeda Pharmaceutical, Pharmicell, Medi-post, NuVasive, Anterogen

For Better Understanding Go With This Free Sample Report Enabled With Respective Tables and Figures( Get Instant 10% Discount ):https://www.eonmarketresearch.com/sample/72746

Global NK Cell Therapy and Stem Cell Therapy Market forecast to 2025 providing information such as company profiles, product picture, and specification, capacity, production, price, cost, revenue, and contact information. Upstream raw materials and equipment and downstream demand analysis are also carried out. The Global NK Cell Therapy and Stem Cell Therapy market trends and marketing channels are analyzed. Finally, the feasibility of new investment projects is assessed and overall research conclusions offered.

Years Considered to Estimate the NK Cell Therapy and Stem Cell Therapy Market Size:

History Year: 2015-2019

Base Year: 2019

Estimated Year: 2020

Forecast Year: 2020-2025

Region Coverage (Regional Production, Demand & Forecast by Countries, etc.):

NK Cell Therapy and Stem Cell Therapy Market regional analysis covers the following regions North America, Europe, Asia-Pacific, South America, Middle East & Africa.

Buy This Premium Report: https://www.eonmarketresearch.com/buy/72746

Product Type Coverage NK Cell Therapy and Stem Cell Therapy Market Size & Forecast, Major Company of Product Type, etc.):

NK Cell TherapyStem Cell Therapy

On the basis of the end users/applications, this report focuses on the status and outlook for major applications/end users, consumption (sales), market share and growth rate for each application, including

Hospital and clinicsRegenerative medicine centersDiagnostic centersResearch institutesOthers

Some of the key questions answered in this report:

Any Questions? Feel Free To Enquire Here. We will Put You On The Right Path: https://www.eonmarketresearch.com/enquiry/72746

Major Point of TOC:

Part I NK Cell Therapy and Stem Cell Therapy Industry Overview

Chapter One:NK Cell Therapy and Stem Cell Therapy Industry Overview

Chapter Two:NK Cell Therapy and Stem Cell Therapy Up and Down Stream Industry Analysis

Part II Asia NK Cell Therapy and Stem Cell Therapy Industry (The Report Company Including the Below Listed But Not All)

Chapter Three:Asia NK Cell Therapy and Stem Cell Therapy Market Analysis

Chapter Four:2015-2020 Asia NK Cell Therapy and Stem Cell Therapy Productions Supply Sales Demand Market Status and Forecast

Chapter Five:Asia NK Cell Therapy and Stem Cell Therapy Key Manufacturers Analysis

Chapter Six:Asia NK Cell Therapy and Stem Cell Therapy Industry Development Trend

Part III North American NK Cell Therapy and Stem Cell Therapy Industry (The Report Company Including the Below Listed But Not All)

Chapter Seven:North American NK Cell Therapy and Stem Cell Therapy Market Analysis

Chapter Eight:2015-2020 North American NK Cell Therapy and Stem Cell Therapy Productions Supply Sales Demand Market Status and Forecast

Chapter Nine:North American NK Cell Therapy and Stem Cell Therapy Key Manufacturers Analysis

Chapter Ten:North American NK Cell Therapy and Stem Cell Therapy Industry Development Trend

Part IV Europe NK Cell Therapy and Stem Cell Therapy Industry Analysis (The Report Company Including the Below Listed But Not All)

Chapter Eleven:Europe NK Cell Therapy and Stem Cell Therapy Market Analysis

Chapter Twelve:2015-2020 Europe NK Cell Therapy and Stem Cell Therapy Productions Supply Sales Demand Market Status and Forecast

Chapter Thirteen:Europe NK Cell Therapy and Stem Cell Therapy Key Manufacturers Analysis

Chapter Fourteen:Europe NK Cell Therapy and Stem Cell Therapy Industry Development Trend

Part V NK Cell Therapy and Stem Cell Therapy Marketing Channels and Investment Feasibility

Chapter Fifthteen:NK Cell Therapy and Stem Cell Therapy Marketing Channels Development Proposals Analysis

Chapter Sixteen:Development Environmental Analysis

Chapter Seventeen:NK Cell Therapy and Stem Cell Therapy New Project Investment Feasibility Analysis

Part VI Global NK Cell Therapy and Stem Cell Therapy Industry Conclusions

Chapter Eighteen:2015-2020 Global NK Cell Therapy and Stem Cell Therapy Productions Supply Sales Demand Market Status and Forecast

Chapter Nineteen:Global NK Cell Therapy and Stem Cell Therapy Industry Development Trend

*** Thanks for reading this article; you can also get region wise report version like North America, Asia-Pacific, Europe, South America, Middle East Africa. ***

About Us:

Eon Market Research(EMR) is a specialized market research, analytics, and solutions company, offering strategic and tactical support to clients for making well-informed business decisions. We are a team of dedicated and impassioned individuals, who believe strongly in giving our very best to what we do and we never back down from any challenge. Eon Market Research offers services such as data mining, information management, and revenue enhancement solutions and suggestions. We cater to industries, individuals, and organizations across the globe, and deliver our offerings in the shortest possible turnaround time.

Get in Touch with Us :

Eon Market Research

Phone: +1 703 879 7090

Email: [emailprotected]

The rest is here:
NK Cell Therapy and Stem Cell Therapy Market Insight | Strategic Industry Evolutionary Analysis Focus on Leading Key Players and Revenue Growth...

For 36 years the professionals at Optimal Health have served the people of the greater Knoxville area. Licensed chiropractor and founder J. Scott Brown and his family established their first clinic in West Knoxville. As his family grew so did Dr. Browns vision. He began to bring on medical doctors, nurse practitioners, and physical rehabilitation professionals, all trained in the most cutting-edge treatments for acute and chronic pain. His practice evolved to become one of the largest integrated medical groups in Knoxville, with four locations in the greater Knoxville area, the newest of which is in Turkey Creek. Integrated Medical Optimal Health in Turkey Creek will offer the same integrated medical treatments as the other three locations, but they have just launched a new, cutting-edge pain management treatment called RP Softwave. It uses gentle radial pulse technology to penetrate deep into the soft tissue area of any joint in the body to relieve pain. Patients typically feel relief after the first treatment.

Dr. Brown has a heart for people and wants to see them live their best lives. Hes wants to help them to fully rehabilitate and regenerate naturally. Having been at the forefront of cutting-edge medical advancements and technologies, in early 2019 the family branched out again and opened Optimal Health Regenerative Aesthetics Medical, which is Knoxvilles only full-service regenerative medicine facility.

He identified ways to help people achieve optimal health through regenerative therapies rather than using traditional methods such as surgery or pain medications. The new practice, Optimal Health Regenerative Aesthetics Medical, in Turkey Creek, uses proven, safe regenerative therapies to restore and repair tissue in the joints as well as to treat other inherited or acquired, acute or chronic conditions. They offer a full range of regenerative services. One of their more sought-after services is stem cell therapy for joint repair. Stem cell therapy uses growth factors to repair and rebuild damaged tissue.

They also offer treatments for vaginal rejuvenation and erectile dysfunction. Many of their female patients have overcome urinary incontinence with the revolutionary O-Shot. As one of only four providers of the innovative GAINSwave erectile dysfunction treatment, Optimal Health has provided results for hundreds of men using this treatment combined with regenerative therapies such as the P-shot for truly life-changing results.

Their medical staff also oversees and provides nutritional counseling through a variety of medical weight loss options. They provide regenerative facial aesthetics using the latest innovative practices and equipment such as combining PRP with micro-needling, also known as the Vampire Facial. The clinics licensed aesthetician begins each consultation with a comprehensive facial scan using the PEAR facial scanner. Optimal Health is the only aesthetics clinic in East Tennessee with this technology. The scan can pinpoint with great accuracy the age of your skin as well as help to identify areas that may need immediate protection or treatment. Optimal Health is also known as the Tennessee Center for Excellence as they are the only provider in the state of Tennessee with exclusive rights for the minimally-invasive hair restoration treatment, SmartGraft. Developed by physicians, medical scientists and engineers, SmartGraft allows Optimal Health to perform hair restoration procedures safely and rapidly while delivering natural, permanent results.

The doctors and other providers at Optimal Health have decades of practice in the fields of physical and regenerative medicine. With a well-rounded knowledge of the human body, medically and holistically, the staff at Optimal Health provide the most effective, non-invasive wellness, aesthetics, and pain management services available. At Optimal Health they love to say, You only live once, so take care of yourself! #YOLOTCOY

11668 Parkside Drive

865.288.4200

Knoxvilleoptimalhealth.com

11660 Parkside Drive

865.288.4300

2905 Tazewell Pike

8906 Kingston Pike

217 N. North Calderwood Street, Alcoa

865-690-1455

Integratedmedicaltn.com

Go here to see the original:
Optimal Health: Cutting Edge Restorative Treatments Cityview - Knoxville City View

The COVID-19 tragedy is expected to create a positive impact on the global cancer stem cells market. The bladder cancer segment is projected to grab major share of the market. The targeted cancerous stem cells segment is projected to observe significant growth. The Asia Pacific region is expected to lead the global market throughout the forecast period. The major players of the market are implementing several strategies to withstand their business amidst this catastrophic situation.

At this moment in time, the whole world is in havoc owing to the abrupt outburst of COVID-19 pandemic. However, this pandemic situation has created a positive impact on the global cancer stem cells market. A latest report published by Research Dive reveals that the global cancer stem cells market is anticipated to gather $1,898.3 billion by 2026, rising at a growth rate of 11.8% from 2019 to 2026. The report segments the global market into application, cancer forms, and region. The report provides comprehensive analysis of the impact of COVID-19 on the key drivers, opportunities, limitations, key segments, and top players of the global market.

Regardless of the outbreak of COVID-19 pandemic, government bodies all over the world are hugely investing on research & development activities to enhance the use of cancer stem cells in the cancer treatments. Additionally, the development of stem cells for stem line banking and developing induced Pluri-Potent Stem Cell (PSC) lines is massively boosting the growth of the cancer stem cells market.

Based on cancer forms, the report categorizes the global cancer stem cells market into brain, breast, bladder, liver, blood, pancreatic, lung, colorectal, and other. The bladder segment is dominating the market ever since 2018 and is predicted to gather $303.9 million by 2026. This segment is expected to grow majorly owing to the rising number of deaths due to bladder cancer, all over the world. According to the U.S. government, bladder cancer is the fifth most occurring cancer among all other types of cancer, and therefore it is optimistically influencing the global market growth throughout the projected period.

Based on application, the report divides the global market into targeted cancerous stem cells and stem cells-cancer therapy. Among these, the targeted cancerous stem cells segment is anticipated to observe significant growth at a CAGR of 13.0% throughout the projected period. As targeted cancerous stem cells have the ability to attract normal cells, they can be used positively to target cancer cells; this factor is greatly boosting the growth of this segment.

Regionally, the report studies the market across North America, Asia-Pacific, Europe, and LAMEA. Among these, the Asia-Pacific region is anticipated to lead the global market by garnering $405.17 million by 2026. This is mostly due to the presence of considerable number of scientists in this region that are involved in R&D activities related to stem cell therapy.

The prominent players in the global cancer stem cells market areMerck KGaA, AbbVie Inc., Irvine Scientific, Stem Cell Technologies Inc., MiltenyiBiotec, Thermo Fisher Scientific Inc., OncoMed Pharmaceuticals, Sino Biological Inc., BioTime Inc., and others.These market players are implementing various tactics to survive during this pandemic situation.

Contact Us:

Mr. Abhishek PaliwalResearch Dive30 Wall St. 8th Floor, New YorkNY 10005 (P)+ 91 (788) 802-9103 (India)+1 (917) 444-1262 (US) TollFree : +1 -888-961-4454Email:[emailprotected]LinkedIn:https://www.linkedin.com/company/research-diveTwitter:https://twitter.com/ResearchDiveFacebook:https://www.facebook.com/Research-DiveBlog:https://www.researchdive.com/blogFollow us on:https://covid-19-market-insights.blogspot.com

Originally posted here:
Early Impacts of COVID-19 on Cancer Stem Cells Market Trends and Future Dynamics 2027 - The Think Curiouser

The latest Stem Cell Banking market research report offers a top to bottom analysis of this business sphere in terms of potential industry size, supply chain, growth dynamics, opportunity analysis, and competitive landscape. Furthermore, it extends through abstracts on various industry segments, inclusive of a rundown of the business scenario across the various regional markets. Additionally, the study provide insights into to the impact of Covid-19 pandemic and recommends strategies that could maximize ROI amid these uncertain times.

Key areas covered in the Covid-19 impact assessment:

An overview of the regional analysis:

Request Sample Copy of this Report @ https://www.aeresearch.net/request-sample/341604

Other important inclusions in the Stem Cell Banking market report:

Key Questions Answered in The Report:

What will the Stem Cell Banking market growth rate?

What are the key factors driving the global Stem Cell Banking market?

Who are the key manufacturers in Stem Cell Banking market space?

What are the market opportunities and overview of the Stem Cell Banking market?

What are sales, revenue, and price analysis of top manufacturers of Stem Cell Banking market?

What are the Stem Cell Banking market opportunities and threats faced by the vendors in the global Stem Cell Banking Industry?

What are sales, revenue, and price analysis by types and applications of Stem Cell Banking Industry?

Request Customization on This Report @ https://www.aeresearch.net/request-for-customization/341604

See the original post:
Stem Cell Banking Market to witness an impressive growth during the forecast pe - News by aeresearch

The Alexander Grass Humanities Institute (AGHI), in conjunction with Great Talk, Inc., hosted a panel of scientists to speak about the ethical considerations and implications of stem cell research on Oct. 21.

The event was moderated by Director of AGHI William Egginton. The four panelists included two experts in genomics research, a journalist who specializes in the role of technology in biomedical research and an expert in medical law.

Dr. Anthony Wynshaw-Boris, chair of the Department of Genetics and Genome Sciences at Case Western Reserve University School of Medicine, discussed how cell lines were cultivated as tools in the past for scientists to use to grow cell cultures to study diseases or develop vaccines. However, there wasnt as much debate about the development of these tools in the past as there is now.

These are scientific tools that we use. The political and social aspects... are arising today because of our polarization, Wynshaw-Boris said.

The panel had an in-depth conversation regarding the ethics of the use of scientific tools such as stem cell lines derived from fetal tissue, embryonic cells, abortion-derived cell lines and cells acquired without consent.

Dr. Eric Green, director of the National Human Genome Research Institute at the National Institutes of Health, argued that the investment that has been made in these cell lines to calibrate them for use in biomedical research cannot be ignored.

Should there be a halt on the use of that mature tool because of its origins that were created in a time when there was a different view? Green asked.

Antonio Regalado, senior editor for biomedicine at MIT Technology Review who writes about the impact of technology on medicine and biomedical research, responded to Greens query.

Regalado brought up the fact that makeup companies have been facing a lot of backlash recently for testing their products on animals. Regalado pointed out that makeup companies could then use a similar argument by saying that since they have already invested money in animal testing procedures, they should not have to find new, less harmful methods of testing.

I don't know that we should rule out the possibility of alternatives if the scientific community decides to put their minds to it. Perhaps an equivalent cell line could be developed, Regalado said.

Diane Hoffman, director of the Law and Health Care Program at the University of Maryland Francis King Carey School of Law, described various perspectives in debate over the ethical concerns of stem cell research.

The challenge, according to Hoffman, is striking a balance between implementing a blanket policy through the government and informing consumers to allow them to make ethical decisions.

Industry wanting innovation, and government wanting safety and efficacy, and consumers wanting access. Those three things are... how we consider these ethical issues, Hoffmann said.

The conversation then shifted to eugenics, the practice of editing human DNA to achieve specific, desirable characteristics, such as eliminating diseases, changing eye color or editing IQ.

Green described an initiative funded by the Human Genome Project, the Ethical, Legal and Social Implications Research Program (ELSI), which focuses on the ethical, legal and social implications of biomedical research.

We can meld together what is scientifically possible to what is the body of evidence of what has come out when we have looked at these ELSI issues and then have conversations... and try to come to consensus on what the guardrails should look like, Green said.

Hoffmann echoed Green, describing the need of the scientific community to also consider allocation of these resources.

Weve got a ways to go in terms of thinking about... how we can be more just in our allocation of medical resources and the benefits of the research were doing, Hoffmann said.

She brought up the idea of giving priority in receiving benefits to vulnerable populations that have been previously harmed by the health-care system.

Wynshaw-Boris added that each study that is conducted needs to address the ELSI considerations mentioned by Green.

Studies have to be done... in partnership with diverse populations, and we have to be committed to that, Wynshaw-Boris said. We have to make progress on it all the time, and that's what we have to be committed to.

The discussion concluded with a consensus among the panelists that the scientific community needs to address social and health inequities as advancements in genetics and genomic techniques continue to occur.

We have to bring more trust to science than exists now, Green said.

Read this article:
Panelists debate the implications and ethics of stem cell research - Johns Hopkins News-Letter

Amid the news explosion that followed President Trumps COVID-19 diagnosis and brief convalescence earlier this month, there was a nugget you might have missed: The antibody treatment from biotech company Regeneron the president tookseemingly to great effecthad been developed in part by means of cells derived from fetal tissue.

Most of the discussion around this revelation concerned whether it showed the president to be a hypocriteeither personally because of his stated pro-life beliefs, or as a matter of policy because his administration has suspended federal funding for scientific research involving fetal tissue. (Both claims were dubious: There was no reason to believe the president knew the provenance of the Regeneron cocktail when he was treated with it, and the kind of fetal-derived cells used to develop the drug were not included in the administrations funding freeze.)

But the news portended a larger problem that may prove important in months to come: the ethical objections other pro-life people may have to new COVID treatmentsincluding vaccineswith similar issues in their development history.

I think its going to test our convictions about these things, said Dr. C. Ben Mitchell, a professor of moral philosophy at evangelical Union University and senior fellow at the Center for Bioethics & Human Dignity. Whether or not we are going to be consistent with our convictions.

Beyond the central aim of ending legal abortion, no issue has so united the pro-life movement over the last few decades as the push to prevent fetal and embryonic remains from being used in medical research. In the 2000s, the battle involved embryonic stem cell research: President Bush prohibited federal funding for research involving new embryonic stem cell lines in 2001, a policy President Obama reversed in 2009. More recently, the issue has been researchers use of fresh tissue from recent abortions, following activist David Daleidens 2015 expos on Planned Parenthoods practice of selling organs from aborted fetuses to medical research companies.

But while pushing for public policy changes and supply chain reforms to make researchers less reliant on ongoing abortions, pro-lifers have also struggled with a parallel issue on a more personal level: whether its permissible to make use of treatments developed via the use of fetal tissue that already exist. If abortion is evil, they ask themselves, then can I in good conscience allow myself to benefit from medicines that rely on the practice?

Such questions are complicated by the fact that, unlike the tissue research that has dominated pro-life policy space in recent years, many medical products in current use, including a number of childhood vaccines, have a connection to abortion that is distant and tenuous. The cell cultures used in developing such medicines are most accurately described not as fetal cells themselves, but as cells that are fetal-derived: Cells originally taken from an aborted fetus that have been cultivated to multiply freely ever since.

The most widely used of these cell lines date back to just a handful of abortions in Europe in the 1960s. The WI-38 cell line, which has been used to develop vaccines for rubella, rabies, measles, mumps, and various other diseases, is derived from the lung tissue of a fetus aborted in Sweden in 1962; The MRC-5 line, used to produce vaccines for Hepatitis A and polio, dates back to 1966. Other lines are used for other purposes: HEK293 cells, which are derived from fetal kidney cells isolated in the Netherlands in the early 1970s, can be used to create virus-like cells that arent able to infect humans. Researchers use these pseudoviruses to test new therapeutics without having to handle live virus themselves, reducing the need for extreme biosafety precautions in laboratory settings. (The aforementioned Regeneron made use of HEK293 cells in this way.)

These cell cultures wont reproduce infinitely, but saying so almost feels like a technicality: Descendants of the WI-38 and MRC-5 lines have been used to create hundreds of millions of doses of vaccines over the past half-century.

Going by any sort of costbenefit analysis, the use of these cell lines has been a force for good in the world. By making use of the remains of a bare handful of elective abortionsabortions that would have taken place whether or not researchers decided to use thema staggering number of people around the world have been spared the miseries of a whole host of wretched and deadly diseases.

But for those who advocate for decoupling from such practices, simply to use the language of cost and benefit in the first place is to give away the game. If thats the measure, they argue, its hard to see how you could oppose any promising medical research, even the most depraved: How can you weigh the suffering of a few unfortunates against the ongoing benefits to all humanity of curing a deadly disease?

These sorts of ethical questions arent the exclusive domain of the pro-life movement. What posture we ought to take toward ill-gotten medical research is a question that has long occupied bioethicists, given how much of the science underpinning our current understanding and practice of medicine was conducted in unethical waysoften even by the standards of their own time, and even more so by the more exacting standards of the present.

The classic example, of course, is the gruesome human experimentation carried out by Nazi doctors in concentration camps, but there are examples closer to home, too: black men in Alabama whose untreated syphilis was allowed to fester for decades so government researchers could observe the progress of the disease, all the while assuring the subjects they were being treated; developmentally disabled children in New York given chocolate milk laced with feces to deliberately infect them with hepatitis as part of an effort to develop a vaccine.

Other ethical issues involve the origin of immortalized cell cultures in particular. The longevity of these cell lines is such that many of them predate modern medical standards on ethical human research, which werent truly codified until the National Commission for the Protection of Human Subjects of Biomedical and Behavior Research, established by Congress for the purpose in 1974, published its Belmont Report in 1979. The oldest such cell line in existence is a culture of cervical cancer cells taken from a woman named Henrietta Lacks in 1951, who died of the disease that same year. Lacks never consented to having her cells cultured; nor did the women who obtained the abortions that resulted in the WI-38 or MRC-5 cells.

These fraught ethical issues are not a thing of the past. After decades of lobbying, the Lacks family finally won a partial concession from the National Institutes of Health in 2013 to place some restrictions on medical access to information about their relatives cells. Pro-life organizations continually push for researchers to divest from and seek alternatives to fetal cell cultures as well.

For some pro-life bioethicists, the vast distance between the harm of the original abortion and the use of the modern treatment in which it resulted means that, while policymakers and biotech firms still have a moral obligation to work toward developing ethically unproblematic alternatives, individuals dont necessarily have a moral duty to abstain from such treatments themselves. Medical ethics are complicated and a matter of conscience, said Tiffany Manor, who directs the Life Ministry of the conservative Lutheran ChurchMissouri Synod. Some modern medical procedures result from past research that was conducted unethically. That doesnt mean that we ought to throw out all of the beneficial procedures.

But others argue that individuals retain a moral duty to keep pressure on the medical research industry by declining the use of such treatments when possible without creating grave risks to public health. The Catholic Churchs Pontifical Academy for Life tried to strike such a balance when it considered the question in 2005:

On a cultural level, the use of such vaccines contributes in the creation of a generalized social consensus to the operation of the pharmaceutical industries which produce them in an immoral way. Therefore, doctors and fathers of families have a duty to take recourse to alternative vaccines (if they exist), putting pressure on the political authorities and health systems so that other vaccines without moral problems become available. They should take recourse, if necessary, to the use of conscientious objection with regard to the use of vaccines produced by means of cell lines of aborted human foetal origin.

The document goes on:

As regards the diseases against which there are no alternative vaccines which are available and ethically acceptable, it is right to abstain from using these vaccines if it can be done without causing children, and indirectly the population as a whole, to undergo significant risks to their health.

You can see the precarious moral tightrope here: It is good, in the mind of pro-life ethicists, to attempt as much as possible not to participate, however indirectly, in the evil act of a long-ago abortion. But one ought not strain so hard to avoid that participation that one thoughtlessly commits another evil act: allowing oneself or ones children to become vectors of otherwise preventable disease, spreading suffering and even death to those around them.

All this, remember, is just the moral calculus that surrounds such vaccine under normal medical circumstances. Throw in a global pandemic and an unprecedented race to treat and cure it, and you begin to get a sense of the scale of the ethical headaches involved.

Take the issue of Regeneron. Since his own positive experience with the companys antibody cocktail, REGN-COV2, President Trump has become its biggest cheerleader; pushing for it to play a major role in COVID treatment going forward. We have hundreds of thousands of doses that are just about ready. I have emergency use authorization all set, he said on October 7. Youre gonna get better, and youre gonna get better really fast.

But both Regenerons drug and a similar antibody treatment currently being developed by Eli Lilly made use of fetal tissue in their developmentnot in the actual manufacture of the drug, as mentioned above, but in creating neutered pseudoviruses to test its effectiveness.

Imagine a person whose doctor has recommended such a drug trying to make a decision in the light of the moral principles suggested by the Pontifical Academy for Life. On the one hand, the drug is a product of fetal tissue research in only the most remote possible way. But the possibility of endangering others by abstaining does not bear considering here, as the cocktail is a treatment, not a vaccine. Further, it is unclear how a person recommended such a treatment by a doctor ought to think about the question of whether there are ethically acceptable alternatives. Other drugs can help manage COVID, of course, but generally speaking their effect is cumulative: Dexamethasone and remdesivir are not replacements for antibody therapy.

To cap the dilemma off, it isnt as though a pro-life person could start off with unproblematic treatments and work up to REGN-COV2 as a matter of last resort: Patients arent prescribed antivirals or steroids for COVID unless theyre already seriously sick, while antibody treatments like Regenerons have been shown to be helpful only if theyre given very early in the course of the disease, before the bodys own immune response has had a chance to kick in.

COVID vaccines in development present further difficulties. First, we dont actually know which of the many vaccines currently being developed will end up the first to pass muster as a safe, effective, and mass-producible weapon against the pandemic. Many of the candidates do not make use of fetal-derived cells in any capacity. Others use such cells only in confirmatory tests, as with Regeneron. Still others use them in the production of the vaccines themselves.

Of the four vaccines seemingly closest to release in America, twothose being developed by Pfizer and Modernawere merely tested on fetal-derived cells. Two others, from Johnson & Johnson and AstraZeneca, are made with them. The latter vaccines Phase III clinical trials were placed on hold earlier this month, but were resumed last week.

Under ordinary circumstances, this would be a no-brainer: Many pro-life people would simply wait for one of the less objectionable vaccines to become available. But during the coronavirus pandemic, where every day that goes by without a vaccine is critical, what happens if Johnson & Johnson or AstraZenecas product is first past the post, and the federal government invests heavily in its development and distribution?

Its unclear whether such a situation would provoke a legal clash. The federal government doesnt have the constitutional authority to mandate vaccines, but states and cities can; all 50 states require children to receive a battery of vaccines before attending public school, although all offer various exemptions for religious, philosophical, and/or other reasons. Whether citizens have a right to such exemptions, however, is less clear: the Supreme Court has upheld mandatory vaccination programs in the past and has separately ruled that the right to practice religion freely does not include liberty to expose the community or the child to communicable disease.

Theres no reason to believe yet that states will choose to go that route. New York Gov. Andrew Cuomo, whose state was racked by the coronavirus this spring and who last year signed a state law ending religious exemptions for childhood vaccines, is thus far messaging that an eventual COVID vaccine will be available to all New York residents who want one.

The likelier scenario may be that such a clash will instead simply play out in the court of public opinion.

One of the nightmare scenarios Ive been thinking about is, say we get a safe and effective vaccine, and it comes from what many would regard as tainted sources, said Mitchell. And so pro-lifers decide not to use the vaccinethey wont be vaccinated. My guess is that there would be a huge uprising in the society saying, Well, youre posing now a public health risk. We now have a vaccine, but youre choosing not to use it. Youre exposing others to it by not taking the vaccine, or youre going to cost our health care system huge amounts of money in treating you when we have a vaccine that could prevent getting COVID-19, but you choose not to. So I think those are going to be an important test of our convictions.

Photograph by Paul Hennessy/NurPhoto/Getty Images.

Read more:
Is the Pro-Life Movement on a Collision Course with the Coronavirus? - The Dispatch

PHILADELPHIA and NEW YORK, Oct. 26, 2020 /PRNewswire/ --Rapid Reshore & Development (RR&D), an alliance of three specialized firms, and BrainStorm Cell Therapeutics, Inc (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced that BrainStorm has selected RR&D as its partner toexpedite site selection and design services for a state-of-the-art manufacturing facility for NurOwn (autologous MSC-NTF) in the U.S.

BrainStorm is investigating NurOwn as a potential treatment for neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS). BrainStorm's most advanced clinical program for NurOwn is in ALS, which is currently being evaluated in a pivotal Phase 3 clinical trial.

BrainStorm seeks to locate, design and construct a new commercial manufacturing facility in the U.S. to prepare for potential commercialization. RR&D, a three-firm services alliance consisting of EwingCole, Facility Logix and Biggins, Lacy, Shapiro & Company, will identify the location and develop the design of BrainStorm's new commercial manufacturing facility.

"We're thrilled to be working with BrainStorm on this project and to have the opportunity to deliver this critical work to our region," said EwingCole CEO, Jared Loos, PE, AIA. "We embrace the spirit of creating potentially life-changing technology and we will do everything we can to move the project forward in an efficient and yet responsible manner."

BrainStorm intends to use the facility primarily for cell therapy production. RR&D will provide custom, streamlined project management, site selection analysis and design/construction management services throughout the project's lifecycle.

Chaim Lebovits, Chief Executive Officer of BrainStorm Cell Therapeutics commented, "Our decision to partner with RR&D was driven by the strong capabilities of the individual partners and their holistic approach to planning, site selection and design services. The expansion of BrainStorm's manufacturing capabilities is a key part of our broader corporate strategy to prepare for potential regulatory approvals of NurOwn and becoming a commercial organization. This new partnership follows our recently announced agreement with Catalent Pharma Solutions to manufacture NurOwn at a scale large enough to meet potential commercial needs at the time of launch. The dedicated, state-of-the-art manufacturing facility developed by RR&D will provide us with important long-term autonomy and strategic flexibility, including the capacity to supply NurOwn for additional disease indications beyond ALS. Together these two partnerships will help ensure that BrainStorm has the manufacturing capacity to meet the needs of patients today and well into the future."

Site selection analyses will begin immediately with the goal of identifying locations that offer a cost-effective solution for BrainStorm's new manufacturing facility. At the same time, the design team will begin developing a conceptual design of the manufacturing facility, based upon input from BrainStorm's process, engineering, and scientific staff, by defining the main steps of the production process and Current Good Manufacturing Practices (cGMP) requirements. The approximately 50,000 square-foot building will contain manufacturing suites, complementary support and infrastructure, and the ability to expand the facility to 100,000 square feet to anticipate future programmatic needs.

About BrainStorm Cell Therapeutics Inc.

BrainStorm Cell Therapeutics Inc.is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. The Company holds the rights to clinical development and commercialization of the NurOwn technology platform used to produce autologous MSC-NTF cells through an exclusive, worldwide licensing agreement. Autologous MSC-NTF cells have received Orphan Drug status designation from theU.S. Food and Drug Administration(FDA) and theEuropean Medicines Agency(EMA) for the treatment of amyotrophic lateral sclerosis (ALS). BrainStorm has fully enrolled a Phase 3 pivotal trial in ALS (NCT03280056), investigating repeat-administration of autologous MSC-NTF cells at sixU.S.sites supported by a grant from theCalifornia Institute for Regenerative Medicine(CIRM CLIN2-0989). The pivotal study is intended to support a filing forU.S.FDA approval of autologous MSC-NTF cells in ALS. BrainStorm also recently receivedU.S.FDA clearance to initiate a Phase 2 open-label multicenter trial in progressive multiple sclerosis (MS). The Phase 2 study of autologous MSC-NTF cells in patients with progressive MS (NCT03799718) completed enrollment inAugust 2020. For more information, visit the company's website atwww.brainstorm-cell.com.

About Rapid Reshore & Development:

Rapid Reshore & Development is an alliance of expert firms providing confidence and support throughout the life sciences industry, representing an evolution from transaction-driven service models to a holistic focus on client needs, integrating an interdisciplinary team customized for a variety of individual projects. To optimize and strengthen confidence in decision-making and speed-to-market, Rapid Reshore & Development alliance was formed to deliver best-in-class professionals with deep experience in all aspects of life sciences' project planning, site selection, design and execution including financial, labor market, development incentives, real estate, design and engineering, and construction management.For additional information, visit: http://www.rapidreshore.com

Safe-Harbor Statement

Statements in this announcement other than historical data and information, including statements regarding future clinical trial enrollment and data, constitute "forward-looking statements" and involve risks and uncertainties that could cause BrainStorm Cell Therapeutics Inc.'s actual results to differ materially from those stated or implied by such forward-looking statements. Terms and phrases such as "may", "should", "would", "could", "will", "expect", "likely", "believe", "plan", "estimate", "predict", "potential", and similar terms and phrases are intended to identify these forward-looking statements. The potential risks and uncertainties include, without limitation, BrainStorm's need to raise additional capital, BrainStorm's ability to continue as a going concern, regulatory approval of BrainStorm's NurOwn treatment candidate, the success of BrainStorm's product development programs and research, regulatory and personnel issues, development of a global market for our services, the ability to secure and maintain research institutions to conduct our clinical trials, the ability to generate significant revenue, the ability of BrainStorm's NurOwn treatment candidate to achieve broad acceptance as a treatment option for ALS or other neurodegenerative diseases, BrainStorm's ability to manufacture and commercialize the NurOwn treatment candidate, obtaining patents that provide meaningful protection, competition and market developments, BrainStorm's ability to protect our intellectual property from infringement by third parties, heath reform legislation, demand for our services, currency exchange rates and product liability claims and litigation,; and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available athttp://www.sec.gov. These factors should be considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking statements. The forward-looking statements contained in this press release are based on the beliefs, expectations and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.

CONTACTS

Brainstorm:Investor Relations: Corey Davis, Ph.D. LifeSci Advisors, LLC Phone: +1 646-465-1138[emailprotected]

Media:Paul TyahlaSmithSolvePhone: + 1.973.713.3768[emailprotected]

Rapid Reshore & Development (RR&D):Media Contact:Zachary DeRitisCommunications Specialist215-409-4249[emailprotected]

SOURCE BrainStorm Cell Therapeutics Inc.; Rapid Reshore & Development (RR&D)

Go here to read the rest:
Rapid Reshore & Development and BrainStorm Cell Therapeutics Announce Agreement to Advance Construction of BrainStorm's US Manufacturing Facility...

GlobeNewswire

BEIJING, China, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Li Auto Inc. (Li Auto or the Company) (Nasdaq: LI), an innovator in Chinas new energy vehicle market, today announced that in October 2020 the Company delivered 3,692 Li ONEs, representing a steady increase compared to September. In October, the Company also achieved strong orders, setting a new monthly record. 2020 Q12020 Q22020 Q32020 JanOct Deliveries2,8966,6048,66021,852 As of October 31, 2020, the Company had 41 retail stores covering 36 cities. Going forward, the Company plans to continue strengthening its direct sales and servicing network to further bolster its footprint and market penetration in China.About Li Auto Inc.Li Auto Inc. is an innovator in Chinas new energy vehicle market. The Company designs, develops, manufactures, and sells premium smart electric SUVs. Through innovative products, technology, and business model, the Company provides customers with safe, convenient, and cost-effective mobility solutions. Li Auto is the first to successfully commercialize extended-range electric vehicles in China. The Company started volume production of its first model, Li ONE, in November 2019. With Li ONE, the Company leverages its in-house technology to create value for its customers, focusing on range extension, smart technology, and autonomous driving solutions. Beyond Li ONE, the Company aims to expand its product line by developing new vehicles to target a broader consumer base.For more information, please visit: http://ir.lixiang.com.Safe Harbor StatementThis press release contains statements that may constitute forward-looking statements pursuant to the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as will, expects, anticipates, aims, future, intends, plans, believes, estimates, likely to, and similar statements. Li Auto may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission (the SEC), in its annual report to shareholders, in press releases and other written materials, and in oral statements made by its officers, directors, or employees to third parties. Statements that are not historical facts, including statements about Li Autos beliefs, plans, and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: Li Autos strategies, future business development, and financial condition and results of operations; Li Autos limited operating history; risks associated with extended-range electric vehicles, Li Autos ability to develop, manufacture, and deliver vehicles of high quality and appeal to customers; Li Autos ability to generate positive cash flow and profits; product defects or any other failure of vehicles to perform as expected; Li Autos ability to compete successfully; Li Autos ability to build its brand and withstand negative publicity; cancellation of orders for Li Autos vehicles; Li Autos ability to develop new vehicles; and changes in consumer demand and government incentives, subsidies, or other favorable government policies. Further information regarding these and other risks is included in Li Autos filings with the SEC. All information provided in this press release is as of the date of this press release, and Li Auto does not undertake any obligation to update any forward-looking statement, except as required under applicable law.For investor and media inquiries, please contact:Li Auto Inc. Investor Relations Email: ir@lixiang.comThe Piacente Group, Inc. Yang Song Tel: +86-10-6508-0677 Email: Li@tpg-ir.comBrandi Piacente Tel: +1-212-481-2050 Email: Li@tpg-ir.com

Visit link:
Will Trevor Lawrence stay at Clemson to avoid the Jets? - Yahoo! Voices

GlobeNewswire

BEIJING, China, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Li Auto Inc. (Li Auto or the Company) (Nasdaq: LI), an innovator in Chinas new energy vehicle market, today announced that in October 2020 the Company delivered 3,692 Li ONEs, representing a steady increase compared to September. In October, the Company also achieved strong orders, setting a new monthly record. 2020 Q12020 Q22020 Q32020 JanOct Deliveries2,8966,6048,66021,852 As of October 31, 2020, the Company had 41 retail stores covering 36 cities. Going forward, the Company plans to continue strengthening its direct sales and servicing network to further bolster its footprint and market penetration in China.About Li Auto Inc.Li Auto Inc. is an innovator in Chinas new energy vehicle market. The Company designs, develops, manufactures, and sells premium smart electric SUVs. Through innovative products, technology, and business model, the Company provides customers with safe, convenient, and cost-effective mobility solutions. Li Auto is the first to successfully commercialize extended-range electric vehicles in China. The Company started volume production of its first model, Li ONE, in November 2019. With Li ONE, the Company leverages its in-house technology to create value for its customers, focusing on range extension, smart technology, and autonomous driving solutions. Beyond Li ONE, the Company aims to expand its product line by developing new vehicles to target a broader consumer base.For more information, please visit: http://ir.lixiang.com.Safe Harbor StatementThis press release contains statements that may constitute forward-looking statements pursuant to the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as will, expects, anticipates, aims, future, intends, plans, believes, estimates, likely to, and similar statements. Li Auto may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission (the SEC), in its annual report to shareholders, in press releases and other written materials, and in oral statements made by its officers, directors, or employees to third parties. Statements that are not historical facts, including statements about Li Autos beliefs, plans, and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: Li Autos strategies, future business development, and financial condition and results of operations; Li Autos limited operating history; risks associated with extended-range electric vehicles, Li Autos ability to develop, manufacture, and deliver vehicles of high quality and appeal to customers; Li Autos ability to generate positive cash flow and profits; product defects or any other failure of vehicles to perform as expected; Li Autos ability to compete successfully; Li Autos ability to build its brand and withstand negative publicity; cancellation of orders for Li Autos vehicles; Li Autos ability to develop new vehicles; and changes in consumer demand and government incentives, subsidies, or other favorable government policies. Further information regarding these and other risks is included in Li Autos filings with the SEC. All information provided in this press release is as of the date of this press release, and Li Auto does not undertake any obligation to update any forward-looking statement, except as required under applicable law.For investor and media inquiries, please contact:Li Auto Inc. Investor Relations Email: ir@lixiang.comThe Piacente Group, Inc. Yang Song Tel: +86-10-6508-0677 Email: Li@tpg-ir.comBrandi Piacente Tel: +1-212-481-2050 Email: Li@tpg-ir.com

See original here:
Spurs' Becky Hammon honored with impressive San Antonio mural - Yahoo! Voices

Globe Newswire

Global Smart Food and Beverage Label Market to Reach $51. 9 Million by 2029. Market Report Coverage - Smart Food and Beverage Label. Market Segmentation.New York, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Smart Food and Beverage Label Market: Focus on Product Type, Application, Industry Analysis and Region Analysis Forecast, 2019-2029" - https://www.reportlinker.com/p05982085/?utm_source=GNW Product Type - RFID, NFC, Temperature Sensing Labels, Others Application - Food, Beverages Regional Segmentation North America U.S., Canada Europe Germany, France U.K. Asia-Pacific and Japan Australia and New Zealand, Japan, and India China Growth Drivers Growing Consumer Demands for Food Authentication Ability of Smart Labels to Enhance Food Safety and Reduce Food Waste Adoption and Implementation of Smart Food Labels by Major Food and Beverage Industry Manufacturers Market Challenges High Implementation Cost for the Smart Food Label Lack of Consumer Knowledge and Accessibility Disproportionality Market Opportunities Growing Confidence and Increasing Consumer Dependence on IoT Technologies Growing Need for Smart Inventory Management in Retail Industry Key Companies Profiled Avery Dennison Corporation, CCL Industries Inc., Honeywell International Inc., Label Insight, Inc., and Sato Holding Corporation, among others Key Questions Answered in this Report: What is the expected global smart food and beverage label market size in terms of value during the period 2018-2029? What are the labeling challenges faced by the food and beverage manufacturers? What is the on-going initiative to transform the global smart food and beverage label market? Which region is the largest market for the global smart food and beverage label market? What is the expected future scenario and the revenue generation by different geographical regions and countries in the smart food and beverage label market such as North America, South America, the U.K., Europe, the Middle East and Africa, China, and Asia-Pacific and Japan? What is the impact of COVID-19 on the smart food and beverage label market? Which product type is currently dominating the smart food and beverage label market, and which is likely to dominate in the future? What are the emerging trends in the global smart food and beverage label market? What are the market dynamics of the global smart food and beverage label market, including market drivers, restraints, and opportunities? What are the major market driving trends for the global smart food and beverage label market in terms business model, market consolidation, and new product offerings? Market Overview The adoption of smart labels has witnessed a sharp increase in the food industry as demand for product authentication and the ability to improve food safety continues to rise.Having connected packaging solutions like smart labels allows end consumers to access all traceable information across the supply chain. Smart labeling provides consumers with a digital source of nutrition, ingredients, allergen, and additional information which may or may not appear on the physical label printed on the packaging or attached to the product itself. Moreover, smart labels also help the consumer to pursue a wide range of products from design to shelf. The rising number of customers with access to packaged food is proliferating relative to the worlds population.The purchasing power of the customer for packaged food, on the other hand, is also growing. The growth in smart labeling is increasing with more and more expenditure on packaged food.Food authenticity evaluation has been required rapidly in the food and beverage industry. The evaluation ensures the originality and safety of any food product that comes into the market.This evaluation is achieved by using specific advanced methods and techniques. Some of the ways include Radio Frequency Identification (RFID) labels that can be attached to food products and can use electromagnetic fields to track products through the supply chain automatically. It brings traceability to the product, which is essential to trace the source of food and avoid counterfeit products. Within the research report, the market is segmented based on product type, application, and region. Each of these segments covers the markets snapshot of the propensity of market revenue, underlying patterns, and trends over the projected years by using analytics on the primary and secondary data obtained. Competitive Landscape The rise in the adoption of smart labeling in the food and beverage industry across the globe has led companies to invest in this industry.The competitive landscape for the smart food and beverage label market demonstrates an inclination toward companies adopting strategies such as product launches along with partnerships and collaborations. The result of the emerging strategies and developments is already surging the market in the form of product launch and developments. Driven by the rapid evolution of the food packaging sector, there has been swift growth in research and development activities by many important players in this market, leading to an increase in the number of product launches and developments since 2017. For instance, in July 2020, Label Insight, Inc. launched Explore Market Navigator, which will help CPG manufacturers improve online discoverability and increase the sales of their products. The business expansion strategy has also been significantly employed for the expansion in the smart food and beverage label market.As the global market continues to expand, businesses operating in this sector are forced to develop collaborative strategies in order to maintain themselves in an extremely competitive market. Key players are also engaging in business expansions in regions where there is a strong demand for smart labeled products.Industry leaders in this market are actively opting for this strategy to improve their market position. For instance, in April 2020, Label Insight, Inc., expanded its operations in the Canadian market to offer SmartLabel and accelerate the adoption of SmartLabel to support the needs of customers. Countries Covered North America U.S. Canada Europe Germany France U.K. China Asia-Pacific and Japan Japan Australia and New Zealand IndiaRead the full report: https://www.reportlinker.com/p05982085/?utm_source=GNWAbout ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.__________________________CONTACT: Clare: clare@reportlinker.comUS: (339)-368-6001Intl: +1 339-368-6001

View original post here:
Total Student Enrollment of China New Higher Education Group Achieves Strong Organic Growth to a New Record High -- Total Number of Enrolled Students...